EE72 The Relative Value of Anti-Obesity Medications Compared to Similar Therapies

Access/coverage for anti-obesity medications (AOMs) is limited compared to treatments other chronic diseases, despite high disease burden. We aimed assess the relative value of AOMs through analysis and comparison cost-benefit and/or clinical benefit covered across selected therapeutic areas. Comparators included a single pharmacotherapy per area (smoking cessation, varenicline; daytime sleepiness, modafinil; migraine, erenumab; fibromyalgia, pregabalin) based on similarity multiple characteristics (e.g., U.S. prevalence, coverage, cost evolution, type indication). A targeted literature review (TLR) was performed identify sources with financial outcomes Parameters extracted evaluated direct indirect medical costs, drivers, associated comorbidities. The TLR identified 2,956 papers. Results were screened relevant data extraction resulting in 89 publications. Smoking obesity represented highest economic burden $300 $260 billion yearly respectively. Weight loss resulted reduction $2,586 costs patient year (PPPY), which higher than reductions $930 PPPY varenicline, $1,045 modafinil, $468 pregabalin utilization showed an increase $924 PPPY. Main drivers savings outpatient, inpatient, emergency room costs. Obesity significantly more comorbidities (17, p<0.05) comparators (migraine=9, smoking=8, sleepiness=5, fibromyalgia=2). costliest cardiovascular disease, stroke, cancer. provide analogues. weight had largest savings. Despite this, are not currently by most health plans. AOM coverage may reduce obesity.